medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2019, Número 2

Siguiente >>

Cardiovasc Metab Sci 2019; 30 (2)


Receptores de membrana acoplados a proteínas G

Nájera N, Martínez‑Vega RP, Portilla‑Martínez A, Ortiz‑Vilchis P, Ceballos G

Idioma: Inglés [English version]
Referencias bibliográficas: 69
Paginas: 50-59
Archivo PDF: 340.73 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009; 459: 356-363.

  2. Strosberg AD. Structure/function relationship of proteins belonging to the family of receptors coupled to GTP-binding proteins. Eur J Biochem. 1991; 196: 1-10.

  3. Hu GM, Mai TL, Chen CM. Visualizing the GPCR network: Classification and evolution. Scientific Reports. 2017; 7: 15495.

  4. Wacker D, Stevens RC, Roth BL. How ligands illuminate GPCR molecular pharmacology. Cell. 2017; 170: 414-427.

  5. Katritch V, Cherezov V, Stevens RC. Structure-function of the G-protein-Coupled receptor superfamily. Annu Rev Pharmacol Toxicol. 2013; 53: 531-556.

  6. Riddy DM, Delerive P, Summers RJ, Sexton PM, Langmead CJ. G protein-coupled receptors targeting insulin resistance, obesity, and type 2 diabetes mellitus. Pharmacol Rev. 2018; 70: 39-67.

  7. Wang J, Gareri C, Rockman HA. G-Protein-coupled receptors in heart disease. Circ Res. 2018; 123: 716-735.

  8. Reimann F, Gribble FM. G protein-coupled receptors as new therapeutic targets for type 2 diabetes. Diabetologia. 2016; 59: 229-233.

  9. Park F. Activators of G Protein signaling in the kidney. J Pharmacol Exp Ther. 2015; 353: 235-242.

  10. Gurbel PA, Kuliopulos A, Tantry US. G-Protein–Coupled receptors signaling pathways in new antiplatelet drug development. Arterioscler Thromb Vasc Biol. 2015; 35: 500-512.

  11. Huang Y, Todd N, Thathiah A. The role of GPCRs in neurodegenerative diseases: avenues for therapeutic intervention. Curr Opin Pharmacol. 2017; 32: 96-110.

  12. Billington CK, Pen RB. Signaling and regulation of G protein-coupled receptors in airway smooth muscle. Respir Res. 2003; 4: 2.

  13. Assie G, Louiset E, Sturm N, René-Corail, F, Groussin L, Bertherat J et al. Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing’s syndrome. J Clin Endocrinol Metab. 2010; 95: E253-E262.

  14. Geppetti P, Veldhuis NA, Lieu TM, Bunnett NW. G Protein-coupled receptors: dynamic machines for signaling pain and itch. Neuron. 2015; 88: 635-649.

  15. Lin HH, Hsiao CC, Pabst C, Hébert J, Schöneberg T, Hamann J. Adhesion GPCRs in regulating immune responses and inflammation. Adv Immunol. 2017; 136: 163-201.

  16. Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017; 16: 829-842.

  17. Paavola KJ, Hall RA. Adhesion G protein-coupled receptors: signaling, pharmacology, and mechanisms of activation. Mol Pharmacol. 2012; 82: 777-783.

  18. Mustafi D, Palczewski K. Topology of class A G protein-coupled receptors: insights gained from crystal structures of rhodopsins, adrenergic and adenosine receptors. Mol Pharmacol. 2009; 75: 1-12.

  19. Ciccarelli M, Sorriento D, Coscioni E, Iaccarino G, Santulli G. Adrenergic receptors. academic press. London UK: Endocrinology of the Heart in Health and Disease: Integrated, Cellular, and Molecular Endocrinology of the Heart; 2009. pp. 285-315.

  20. Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol. 2006; 26: 219-233.

  21. Sheth S, Brito R, Mukherjea D, Rybak LP, Ramkumar V. Adenosine receptors: expression, function and regulation. Int J Mol Sci. 2014; 15: 2024-2052.

  22. Berne RM. The role of adenosine in the regulation of coronary blood flow. Circ Res. 1980; 47: 807-813.

  23. Lerman BB, Belardinelli L. Cardiac electrophysiology of adenosine. Basic and clinical concepts. Circulation. 1991; 83: 1499-1509.

  24. Singh KD, Karnik SS. Angiotensin receptors: structure, function, signaling and clinical applications. J Cell Signal. 2016; 1: 111.

  25. Li Y, Li XH, Yuan H. Angiotensin II type-2 receptor-specific effects on the cardiovascular system. Cardiovasc Diagn Ther. 2012; 2: 56-62.

  26. Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M. The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: Focus on angiotensin-(1-7). Physiol Rev. 2018; 98: 505-553.

  27. Lavoie JL, Sigmund CD. Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system. Endocrinology. 2003; 144: 2179-2183.

  28. Bortolato A, Doré AS, Hollenstein K, Tehan BG, Mason JS, Marshall FH. Structure of Class B GPCRs: new horizons for drug discovery. Br J Pharmacol. 2014; 171: 3132-3145.

  29. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA. 1992; 89: 8641-8645.

  30. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010; 1: 8-23.

  31. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AMF, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes. 2002; 51 (suppl 3): S434-S442.

  32. Hauger RL, Risbrough V, Brauns O, Dautzenberg FM. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets. 2006; 5: 453-479.

  33. Slater PG, Yarur HE, Gysling K. Corticotropin-releasing factor receptors and their interacting proteins: functional consequences. Mol Pharmacol. 2016; 90: 627-632.

  34. Masi L, Brandi ML. Calcitonin and calcitonin receptors. Clin Cases Miner Bone Metab. 2007; 4: 117-122.

  35. Vilardaga JP, Romero G, Friedman PA, Gardella TJ. Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell Mol Life Sci. 2011; 68: 1-13.

  36. Henning RJ, Sawmiller DR. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res. 2001; 49: 27-37.

  37. Chun L, Zhang WH, Liu JF. Structure and ligand recognition of class C GPCRs. Acta Pharmacol Sin. 2012; 33: 312-323.

  38. Pin JP, Acher F. The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord. 2002; 1: 297-317.

  39. Simeone TA, Sanchez RM, Rho JM. Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system. J Child Neurol. 2004; 19: 343-360.

  40. Rondard P, Goudet C, Kniazeff J, Pin JP, Prezeau L. The complexity of their activation mechanism opens new possibilities for the modulation of mGlu and GABABclass C G protein-coupled receptors. Neuropharmacology. 2011; 60: 82-92.

  41. Betke KM, Wells CA, Hamm HE. GPCR mediated regulation of synaptic transmission. Prog Neurobiol. 2012; 96: 304-321.

  42. Grupo de estudio CINAREN, Torregrosa JV, Morales E, Díaz JM, Crespo J, Bravo J et al. Cinacalcet en el manejo del hiperparatiroidismo secundario normocalcémico tras el trasplante renal: estudio multicéntrico de un año de seguimiento. Nefrología. 2014; 34: 62-68.

  43. Francia S, Pifferi S, Menini A, Tirindelli R. Vomeronasal receptors and signal transduction in the vomeronasal organ of mammals. In: Mucignat-Caretta C, editor. Neurobiology of chemical communication. Chapter 10. Boca Raton (FL): CRC Press/Taylor & Francis; 2014.

  44. Meredith M. Human vomeronasal organ function: a critical review of best and worst cases. Chem Sens. 2001; 26: 433-445.

  45. Trotier D. Vomeronasal organ and human pheromones. Eur Ann Otorhinolaryngol Head Neck Dis. 2011; 128: 184-190.

  46. Sanematsu K, Yoshida R, Shigemura N, Ninomiya Y. Structure, function, and signaling of taste G-protein-coupled receptors. Curr Pharm Biotechnol. 2014; 15: 951-961.

  47. Melis M, Tomassini-Barbarossa IT. Taste perception of sweet, sour, salty, bitter, and umami and changes due to l-Arginine supplementation, as a function of genetic ability to taste 6-n-propylthiouracil. Nutrients. 2017; 9: 541.

  48. Running CA, Craig BA, Mattes RD. Oleogustus: the unique taste of fat. Chem Senses. 2015; 40: 507-516.

  49. Cygankiewicz AI, Maslowska A, Krajewska WM. Molecular basis of taste sense: involvement of GPCR receptors. Crit Rev Food Sci Nutr. 2014; 54 (6): 771-780.

  50. Ambaldhage VK, Puttabuddi JH, Nunsavath PN, Tummuru YR. Taste disorders: A review. JIAOMR. 2014; 26: 69-76.

  51. Feng P, Huang L, Wang H. Taste bud homeostasis in health, disease, and aging. Chem Senses. 2014; 39: 3-16.

  52. Henkin RI. Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction. Drug Saf. 1994; 11: 318-377.

  53. Prabhua Y, Mondal S, Eichingera L, Noege AA. A GPCR involved in post aggregation events in Dictyostelium discoideum. Developl Biol. 2007; 312: 29-43.

  54. Basith S, Cui M, Macalino SJY, Park J, Clavio NAB, Kang S et al. Exploring G protein-coupled receptors (GPCRs) ligand space via cheminformatics approaches: Impact on rational drug design. Front Pharmacol. 2018; 9: 128.

  55. Wright SC, Kozielewicz P, Kowalski-Jahn M, Petersen J, Bowin CF, Slodkowicz G et al. A conserved molecular switch in class F receptors regulates receptor activation and pathway selection. Nature Communication. 2019; 10: 667.

  56. Bjarnadóttir TK, Fredriksson R, Schiöth HB. The adhesion GPCR: a unique of G protein-coupled receptors with important roles in both central and peripheral tissues. Cell Mol. Life Sci. 2007; 64: 2014-2119.

  57. Kobilka BK. G protein coupled receptor structure and activation. Biochim Biophys Acta. 2007; 1768: 794-807.

  58. Gurevich VV, Gurevich EV. Molecular mechanisms of GPCR signaling: a structural perspective. Int J Mol Sci. 2017; 18: 2519.

  59. Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors. Mol Pharmacol. 2012; 82: 777-783.

  60. Birnbaumer L. The discovery of signal transduction by G proteins: a personal account and an overview of the initial findings and contributions that led to our present understanding. Biochim Biophys Acta. 2007; 1768 (4): 756-771.

  61. Milligan G, Kostenis E. Heterotrimeric G-proteins: a short history. Br J Pharmacol. 2006; 147 (Suppl 1): S46-S55.

  62. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation. 1993; 87: 1816-1828.

  63. Syrovatkina V, Alegre KO, Dey R, Huang XY. Regulation, signaling and physiological functions of G-proteins. J Mol Biol. 2016; 428: 3850-3868.

  64. Heider D, Hauke S, Pyka M, Kessler D. Insights into the classification of small GTPases. Adv Appl Bioinforma Chem. 2010; 3: 15-24.

  65. Song S, Cong W, Zhou S, Shi Y, Dai W, Zhang H et al. Small GTPases: structure, biological function and its interaction with nanoparticles. Asian J Pharm Sci. 2019; 14: 30-39.

  66. Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci. 2005; 118: 843-846.

  67. Colicelli J. Human RAS superfamily proteins and related GTPases. Sci STKE. 2004; (250): RE13.

  68. Hashemi M, Hoshyar R, Ande SR, Chen QM, Solomon C, Zuse A et al. Mevalonate cascade and its regulation in cholesterol metabolism in different tissues in health and disease. Curr Mol Pharmacol. 2017; 10: 13-26.

  69. Alizadeh J, Zeki AA, Mirzae N, Tewary S, Moghadam AR, Glogowska A et al. Mevalonate cascade inhibition by simvastatin induces the intrinsic apoptosis pathway via depletion of isoprenoids in tumor cells. Scientific Reports. 2017; 7: 44841.




2020     |     www.medigraphic.com